Bcr-Abl
Los inhibidores de Bcr-Abl son terapias dirigidas que inhiben la proteína de fusión Bcr-Abl, formada debido a la translocación del cromosoma Filadelfia y que es un impulsor de la leucemia mieloide crónica (LMC). Esta proteína también influye en la angiogénesis, contribuyendo a la progresión tumoral. Los inhibidores de Bcr-Abl son cruciales en el tratamiento de la LMC y se están explorando por su potencial para inhibir la angiogénesis en varios tipos de cáncer. En CymitQuimica, ofrecemos inhibidores de Bcr-Abl de alta calidad para apoyar su investigación en biología del cáncer, angiogénesis y terapias dirigidas.
Se han encontrado 102 productos de "Bcr-Abl"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Multi-kinase inhibitor 1
CAS:<p>Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.</p>Fórmula:C20H17F3N4O3Pureza:99.34%Forma y color:SolidPeso molecular:418.37Flumatinib
CAS:<p>Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.</p>Fórmula:C29H29F3N8OPureza:99.39% - 99.95%Forma y color:SolidPeso molecular:562.59AG1024
CAS:<p>AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).</p>Fórmula:C14H13BrN2OPureza:98% - 99.37%Forma y color:SolidPeso molecular:305.17Olverembatinib dimesylate
CAS:<p>Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).</p>Fórmula:C29H27F3N6O·2CH4O3SPureza:97.66% - >99.99%Forma y color:SolidPeso molecular:724.77Dasatinib N-oxide
CAS:<p>Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.</p>Fórmula:C22H26ClN7O3SPureza:98.54% - 99.94%Forma y color:SolidPeso molecular:504Olverembatinib
CAS:<p>Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).</p>Fórmula:C29H27F3N6OPureza:98.53% - >99.99%Forma y color:SolidPeso molecular:532.56GNF-2
CAS:<p>GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.</p>Fórmula:C18H13F3N4O2Pureza:98.17% - ≥95%Forma y color:SolidPeso molecular:374.32GMB-475
CAS:<p>GMB-475, a PROTAC-based BCR-ABL1 inhibitor, tackles drug resistance by promoting VHL-mediated degradation.</p>Fórmula:C43H46F3N7O7SPureza:98.78% - >99.99%Forma y color:SolidPeso molecular:861.93KW-2449
CAS:<p>KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.</p>Fórmula:C20H20N4OPureza:98.43% - 99.69%Forma y color:SolidPeso molecular:332.4BGG463
CAS:<p>BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.</p>Fórmula:C30H29F3N6O3Pureza:95.05% - >99.99%Forma y color:SolidPeso molecular:578.58Asciminib
CAS:<p>Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).</p>Fórmula:C20H18ClF2N5O3Pureza:98.82% - 99.70%Forma y color:SolidPeso molecular:449.84Imatinib
CAS:<p>Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit</p>Fórmula:C29H31N7OPureza:99.42% - 99.94%Forma y color:Off White PowderPeso molecular:493.6XL228
CAS:<p>XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).</p>Fórmula:C22H31N9OPureza:99.07%Forma y color:SolidPeso molecular:437.54Bafetinib
CAS:<p>Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.</p>Fórmula:C30H31F3N8OPureza:94.16% - 99.68%Forma y color:SolidPeso molecular:576.62GNF-5
CAS:<p>GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.</p>Fórmula:C20H17F3N4O3Pureza:98% - 99.94%Forma y color:SolidPeso molecular:418.37Flumatinib mesylate
CAS:<p>Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.</p>Fórmula:C30H33F3N8O4SPureza:99.82%Forma y color:SolidPeso molecular:658.69CZC-8004
CAS:<p>CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.</p>Fórmula:C17H16FN5Pureza:99.29%Forma y color:SolidPeso molecular:309.34Adaphostin
CAS:<p>Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.</p>Fórmula:C24H27NO4Pureza:98.29%Forma y color:SolidPeso molecular:393.48Nilotinib monohydrochloride monohydrate
CAS:<p>Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosine</p>Fórmula:C28H22F3N7O·HCl·H2OPureza:99.93%Forma y color:SolidPeso molecular:583.99AST 487
CAS:<p>AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.</p>Fórmula:C26H30F3N7O2Pureza:98.17% - 99.56%Forma y color:SolidPeso molecular:529.56PD173955
CAS:<p>PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and</p>Fórmula:C21H16Cl2N4OSPureza:98.52% - 98.99%Forma y color:SolidPeso molecular:443.35Bosutinib hydrate
CAS:<p>Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.</p>Fórmula:C26H31Cl2N5O4Pureza:99.87%Forma y color:SolidPeso molecular:548.46BCR-ABL-IN-7
CAS:<p>BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.</p>Fórmula:C19H16FN3O3SPureza:98.28%Forma y color:SolidPeso molecular:385.41BCR-ABL1-IN-1
CAS:<p>BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.</p>Fórmula:C18H12F3N3O2Forma y color:SolidPeso molecular:359.3Debio 0617B
CAS:<p>Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.</p>Fórmula:C28H23ClF3N7O2Forma y color:SolidPeso molecular:581.98Antiproliferative agent-30
CAS:<p>Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against</p>Fórmula:C24H26N4O4Forma y color:SolidPeso molecular:434.49BCR-ABL-IN-6
CAS:<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Fórmula:C27H22F3N5O2Forma y color:SolidPeso molecular:505.49c-ABL-IN-2
CAS:<p>C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.</p>Fórmula:C21H20N4OForma y color:SolidPeso molecular:344.41AN-019
CAS:<p>AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.</p>Fórmula:C25H17F6N5OPureza:98.99%Forma y color:SolidPeso molecular:517.43CHMFL-ABL-053
CAS:<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Fórmula:C28H26F3N7O2Forma y color:SolidPeso molecular:549.55BGB659
CAS:<p>BGB659 is effective inhibitor of RAF.</p>Fórmula:C29H29F3N4O3Pureza:98%Forma y color:SolidPeso molecular:538.56Tyrphostin AG 568
CAS:<p>Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.</p>Fórmula:C13H9N5O2Pureza:98%Forma y color:SolidPeso molecular:267.24BCR-ABL-IN-5
CAS:<p>BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.</p>Fórmula:C25H21Cl2N5O2Forma y color:SolidPeso molecular:494.37AFG210
CAS:<p>AFG210 is a novel first-generation “type II” FLT3 inhibitor.</p>Fórmula:C19H14F3N3O2Forma y color:SolidPeso molecular:373.33AP 24149
CAS:<p>AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.</p>Fórmula:C23H24N5OPForma y color:SolidPeso molecular:417.44CpCDPK1/TgCDPK1-IN-1
CAS:<p>CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.</p>Fórmula:C18H17N5Pureza:99.61%Forma y color:SolidPeso molecular:303.36BCR-ABL-IN-2
CAS:<p>BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).</p>Fórmula:C24H25Cl2N5O3Pureza:98%Forma y color:SolidPeso molecular:502.39PF-06651481-00
CAS:<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Fórmula:C26H29Cl2N5O3Pureza:97.01%Forma y color:SolidPeso molecular:530.45BCR-ABL-IN-1
CAS:<p>BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.</p>Fórmula:C23H21F4N5OPureza:98%Forma y color:SolidPeso molecular:459.44LS-104
CAS:<p>LS-104 is a JAK2 inhibitor.</p>Fórmula:C19H16N2O3Forma y color:SolidPeso molecular:320.34PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Fórmula:C20H13Cl2FN4OForma y color:SolidPeso molecular:415.25PPY A
CAS:<p>PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase and inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl gene-transformed cells</p>Fórmula:C22H20N4O2Pureza:98.77%Forma y color:SolidPeso molecular:372.42Nilotinib hydrochloride
CAS:<p>Nilotinib HCl (AMN-107 HCl), an oral Bcr-Abl inhibitor, targets neuroinflammation, cognitive issues, and chronic myelogenous leukemia.</p>Fórmula:C28H23ClF3N7OPureza:>99.99%Forma y color:SolidPeso molecular:565.98Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Fórmula:C10H18O4Pureza:≥98%Forma y color:SolidPeso molecular:202.25BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Fórmula:C27H24ClF2N5O4Forma y color:SolidPeso molecular:555.96Risvodetinib
CAS:<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Fórmula:C33H34N8O2Forma y color:SolidPeso molecular:574.68CT-721
CAS:<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Fórmula:C30H29ClN6OPureza:98%Forma y color:SolidPeso molecular:525.04HG-7-86-01
CAS:<p>HG-7-86-01 is a selective type II tyrosine kinase inhibitor with antiproliferative activity against mutant T315I- Bcr-Abl for chronic myeloid leukemia (CML).</p>Fórmula:C28H21F3N6O2SPureza:99.07%Forma y color:SolidPeso molecular:562.57Tyrosine kinase-IN-9
CAS:<p>Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</p>Fórmula:C20H14ClN3O3Forma y color:SolidPeso molecular:379.796PP487
CAS:<p>PP487 is a dual tyrosine kinase/PI(3)K inhibitor, exhibiting IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. It is applicable in cancer research [1].</p>Fórmula:C14H14BrN5OForma y color:SolidPeso molecular:348.2
